Facing a major patent cliff for Eliquis, high debt load, and underperforming drug launches.

Benefits from a highly favorable regulatory environment where the FDA is reducing barriers and accelerating approvals for cell and gene therapies, including CAR-T.

Cited as a large-cap pharma company likely to be an acquirer, but the investment thesis favors owning the smaller biotech targets instead.

Bullish view as the stock has broken a long-term downtrend. At $54, there is potential for it to run towards its prior highs around $63.

The host calls this a 'strong pass,' advising against buying the company due to a series of drug pipeline disappointments and the inherent volatility of the industry.

Mentioned as a well-performing stock in the healthcare sector, which is attracting investor attention as a defensive play offering 'bond-like dividend yields with potentially equity-like upside'.

Stock is down 17% due to underperformance in the pharma sector caused by political pressure to lower U.S. drug prices.